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ABSTRACT
The anabolic effects of b2-adrenoceptor (b2-AR) agonists on
skeletal muscle have been demonstrated in various species.
However, the clinical use of b2-AR agonists for skeletal muscle
wasting conditions has been limited by their undesired cardio-
vascular effects. Here, we describe the preclinical pharmaco-
logical profile of a novel 5-hydroxybenzothiazolone (5-HOB)
derived b2-AR agonist in comparison with formoterol as a
representative b2-AR agonist that have been well character-
ized. In vitro, 5-HOB has nanomolar affinity for the human
b2-AR and selectivity over the b1-AR and b3-AR. 5-HOB also
shows potent agonistic activity at the b2-AR in primary skeletal
muscle myotubes and induces hypertrophy of skeletal muscle
myotubes. Compared with formoterol, 5-HOB demonstrates
comparable full-agonist activity on cAMP production in skeletal
muscle cells and skeletal muscle tissue–derived membranes. In
contrast, a greatly reduced intrinsic activity was determined in
cardiomyocytes and cell membranes prepared from the rat heart.
In addition, 5-HOB shows weak effects on chronotropy, ino-
tropy, and vascular relaxation compared with formoterol. In vivo,
5-HOB significantly increases hind limb muscle weight in rats
with attenuated effects on heart weight and ejection fraction,
unlike formoterol. Furthermore, changes in cardiovascular pa-
rameters after bolus subcutaneous treatment in rats and rhesus
monkeys are significantly lower with 5-HOB compared with
formoterol. In conclusion, the pharmacological profile of 5-HOB
indicates superior tissue selectivity compared with the con-
ventional b2-AR agonist formoterol in preclinical studies and
supports the notion that such tissue-selective agonists should
be investigated for the safe treatment of muscle-wasting condi-
tions without cardiovascular limiting effects.
Introduction
Skeletal muscle atrophy is a common debilitating comor-
bidity currently without any approved treatment options.
In humans, skeletal muscle atrophy occurs under various
physiologic and disease conditions, such as: following an
injury resulting in immobilization, critical illness, burns,
cancer, congestive heart failure, liver disease, chronic obstruc-
tive pulmonary disease, chronic kidney disease, acquired
immune deficiency syndrome, and diabetes. The reduction
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in strength and endurance associated with the involuntary
loss of muscle mass results in functional limitations, loss of
independence, a reduced quality of life, increased disability,
and increased mortality (Dudgeon et al., 2006; Lynch et al.,
2007; Thomas, 2007).
b-Adrenoceptors (ARs) are a subfamily of G protein-coupled
receptors that are activated by the endogenous catecholamines,
adrenaline and noradrenaline. They regulate diverse phys-
iologic functions, from heart pacemaker activity, myocardial
contractility, and vascular and bronchial smooth muscle tone,
to glucose and lipidmetabolism (Zheng et al., 2005). b-ARs can
be classified into three distinct subtypes, b1, b2, and b3, which
share 65%–70% homology between these subgroups. b1-ARs
are the main subtype in the heart whereas b2-ARs are
prominently found in smooth and skeletal muscles and b3-
Ars, in white and brown adipose tissues, gallbladder, and
urinary bladder (Kim et al., 1991; Sarsero and Molenaar,
1995; Ursino et al., 2009). Synthetic b2-AR agonists were
initially developed to facilitate bronchodilation to relieve
asthma and chronic obstructive pulmonary disease (Solis-Cohen,
1990). However, several studies have shown the efficacy of
b2-AR agonists in addressing skeletal muscle wasting condi-
tions in animal models such as cancer cachexia and sarcope-
nia (Busquets et al., 2004; Ryall et al., 2007) and also in
human clinical trials in orthopedic patients, cancer cachexia,
and muscular dystrophy patients (Martineau et al., 1992;
Maltin et al., 1993; Kissel et al., 2001; Fowler et al., 2004;
Skura et al., 2008; Greig et al., 2014). In animals, b2-AR
agonists can prevent skeletal muscle atrophy (e.g., injury)
and elicit hypertrophy, which is associated with improvements
in strength in both fast- and slow-twitch muscles (Ryall et al.,
2006, 2008;Burniston et al., 2007). The increase inmusclemass
results from an increase in protein synthesis and a decrease
in protein degradation, mediated via b2-AR coupling to Gas
followed by adenylate cyclase induction, and a consequent
increase in intracellular cAMP concentration. In addition,
the Gbg subunits are thought to activate the PI3K-Akt
pathway (Lynch and Ryall, 2008; Ryall et al., 2010).
Besides the induction of skeletal muscle hypertrophy
and the inhibition of atrophy, b-AR stimulation also serves
as a powerful way to increase cardiac output in response to
stress or exercise. As a consequence, the clinical use of b2-AR
agonists has been limited by their cardiovascular effects, for
example, tachycardia and palpitation (Inamizu et al., 1984;
Löfdahl and Svedmyr, 1989). Moreover, sustained b-AR stim-
ulation can promote pathologic cardiac remodeling such as
cardiomyocyte hypertrophy and apoptosis, and ultimately
contribute to heart failure. As shown in studies using heart-
specific overexpression of b1-AR- and b-AR subtype–knockout
animal models, b1-AR plays a predominant role in regulation
of contractility and pathologic remodeling effects (Rohrer et al.,
1996; Chruscinski et al., 1999; Engelhardt et al., 1999), b-AR-
induced positive contractile responses in human heart are
also predominantlymediated by b1-AR stimulation, but b2-AR
causes a significant positive chronotropic and inotropic effect
(Levine and Leenen, 1989; Brodde, 1991).
Here, we describe the preclinical pharmacological profile
of a novel 5-hydroxybenzothiazolone (5-HOB) b2-AR agonist,
(R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-
hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one, which
is both b-AR subtype and tissue selective. Our data demon-
strate that 5-HOB has strong anabolic and functional skeletal
muscle effects at doses associatedwith reduced cardiovascular
effects in animal models, indicating a substantially improved
safety margin compared with the b2-AR agonist formoterol
when administered systemically. To understand the unique
efficacy profile of 5-HOB, a series of in vitro studies was
carried out, including binding affinity measurements and
b2-AR kinetics, receptor selectivity and cellular activity, as





5-hydroxybenzo[d]thiazol-2(3H)-one (5-HOB; Fig. 1A) was synthesized at
Novartis Pharma AG (Basel, Switzerland) according to the synthetic
method described in WO 2014132205. Formoterol hemifumarate was
purchased from Tocris Bioscience (cat. no. 1448; Bristol, UK) and AK
Scientific (cat. no. 67361;Mountain View, CA). Doses of formoterol are
quoted as the nonsalt (molecular weight ratio5 1.169). 2-Hydroxypropyl
b-cyclodextrin was purchased from Sigma-Aldrich (cat. no. 332593;
St. Louis, MO).
Cell Culture Techniques
Chinese hamster ovary (CHO) cells stably expressing recombinant
human b1- and b2-AR with matched expression levels were made
Fig. 1. (A) Chemical structure of 5-HOB: (R)-7-(2-(1-(4-
butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-
5-hydroxybenzo[d]thiazol-2(3H)-one. (B) Effect of formoterol
and 5-HOB on cAMP production in membranes isolated
from Wistar rat gastrocnemius muscle and from the heart.
Percentages of cAMP response were determined relative
to the Emax of formoterol in skeletal muscle membranes.
Data shown are means 6 S.E.M. of three independent
experiments. *P, 0.05; **P, 0.01 on efficacy of 5-HOB vs..
formoterol in heart membranes and #P, 0.05; ##P, 0.01 in
skeletal muscle membrane (T-test, unpaired).
5-HOB, Skeletal Muscle Selective b2-Agonist 189
 at A








in-house and maintained as described before (Battram et al.,
2006). Human embryonic kidney 293 (HEK293) cells expressing
human b3-AR were maintained at Eurofins Panlabs Taiwan Ltd.
according to standard conditions. b3-AR expression levels in
HEK293 were comparable to the b1-AR and b2-AR receptors levels
in the CHO cells (Bmax values 0.55, 0.334, 0.356 pmol/mg protein,
respectively).
Skeletal muscle cells. Human primary fetal skeletal muscle
cells (skMC, cat. no. CC-2561 female; Lonza, Basel, Switzerland)
were maintained and differentiated for 5 days as described pre-
viously (Lach-Trifilieff et al., 2014). To enhance differentiation the
medium was supplemented with 1 mM SB431542 (Sigma-Aldrich).
Primary myoblasts were isolated from the quadriceps of Wistar
Han rats at the age of 2–3 days, mixed gender (neonatal); from the
gastrocnemius of adult male beagle dogs; and from the gastrocne-
mius of adult female rhesus monkeys. Briefly, for digestion, muscle
pieces were incubated in a dissociation medium [Dulbecco’s modi-
fied Eagle’s medium (DMEM)/F12; 6 mM NaHCO3; 1 insulin-
transferrin-selenium (ITSX); 1% phosphatidylserine (PS)] containing
collagenase IA (600 IU/ml; Sigma-Aldrich) and hyaluronidase I-S
(600 IU/ml; Sigma-Aldrich) for 10 minutes at 37°C. Supernatants
were discarded and tissue pieces were incubated and agitated in
the dissociation medium containing dispase II (2.5 mg/ml; Roche,
Mannheim, Germany) for a further 15 minutes at 37°C. The super-
natant was collected and strained through a 100 mmmesh filter into
ice-cold stop medium (DMEM/F12; 10% FBS; 1% ITSX; 1% PS),
centrifuged at 130g at 4°C for 5 minutes. Pellets containing cells
were resuspended in the same medium and preplated to separate
fibroblasts from muscle cells. After 1 hour the supernatant contain-
ing muscle cells was collected and centrifuged at 130g at 4°C for
5 minutes. Cells were resuspended in the stop medium and plated
in 384-well plates coated with Matrigel (Falcon, Bedford, MA) or
collagen (Sigma-Aldrich). On the following day this medium was ex-
changed for one containing reduced serum content [4% fetal bovine
serum (FBS)], and two days later cells were transferred to a
differentiation medium (DMEM/F12; 2% HS; 1% ITSX; 1% PS) for
5 days.
Cardiomyocytes. Human iPS-derived cardiomyocytes (cat. no.
CMC-100-110-001, female; Fujifilm Cellular Dynamics, Inc., Madi-
son,WI) were plated on fibronectin (Sigma-Aldrich) and maintained
according to the supplier’s protocol. Primary neonatal rat ventric-
ular cardiomyocytes were prepared from 2- to 3-day-old pups of
Wistar Han rats. Briefly, hearts were quickly excised, the atria
were cut off, then the ventricles were minced and digested at
4°C overnight in calcium-free HEPES-buffered Hanks’ solution,
pH 7.4, plus trypsin (100 IU in 10 ml). Soybean Trypsin Inhibi-
tor [2 mg/ml in Hanks’ balanced salt solution (HBSS); Worthing-
ton, Lakewood] was added and further digestion was performed
at 37°C for 45 minutes by collagenase II (300 IU/ml in HBSS;
Worthington). The isolated cells were centrifuged at 80g, room temper-
ature for 5 minutes. The cell pellet was resuspended in preplating
medium containing DMEM/F12, 4.5 mM NaHCO3, 1 Primocin,
5% fetal calf serum (FCS), and 5% HS and preplated for 1 hour to
reduce the contribution of nonmyocardial cells. For the cAMP
assay, cardiomyocytes from the supernatant were transferred
into 384-well plates coated with collagen in medium containing
DMEM/F12; 4.5 mM NaHCO3; 1 Primocin; 2% FCS; 2% HS; 1%
ITSX; 10 mM BrdU. After 24 hours cells were transferred to a
starvation medium without FCS and HS, and the cAMP assay was
performed on the following day.
Binding Kinetics
CHO cells expressing the human b2-AR were used for cell mem-
brane preparation for radioligand binding studies. Cell membranes
were prepared and competition binding assays were performed as
described previously (Sykes and Charlton, 2012). To obtain affin-
ity estimates for unlabeled 5-HOB, [3H]-DHA competition binding
experiments were performed. [3H]-DHA (Perkin Elmer, Waltham,
MA) was used at a concentration of approx. 0.6 nM such that the
calculated total binding never exceeded more than 10% of total ligand
concentration added, therefore avoiding ligand depletion. [3H]-DHA
was incubated in the presence of the indicated concentration of
unlabeled 5-HOB and CHO-cell membranes expressing the b2-AR
at 37°C in assay binding buffer in 96-deep well plates with gentle
agitation for 2.5 hours to ensure equilibriumwas reached. The kinetic
parameters of unlabeled 5-HOB were assessed using the methodology
of Sykes et al. 2010. All experiments were analyzed by nonlinear
regression using GraphPad Prism 5.0 (GraphPad Software, La Jolla,
CA). Competition displacement binding data were fitted to sigmoidal
(variable slope) curves using a four parameter logistic equation.
IC50 values obtained from the inhibition curves were converted to
Ki values using the method of Cheng and Prusoff (1973). [
3H]-DHA
association data were fitted as follows to a global fitting model using
GraphPad Prism 5.0 to simultaneously calculate kon and koff. Associ-
ation and dissociation rates for unlabeled antagonists were calculated
using the equations described by Motulsky and Mahan (1984). The
percentage occupancy was calculated by estimating the concentration
of each compound producing a cAMP response equivalent to 40% of the
isoprenaline control in the cAMP assay [percentage of control (EC40),
i.e., identical system response levels]. kobs curves were then simulated
using the kinetic parameters koff and kon at the concentration of
compound producing a response equivalent to the percentage of
control [EC40]. From this type of analysis it was possible to estimate
the percentage of receptors occupied by each agonist (Sykes and
Charlton, 2012).
In Vitro Cell-Based Assays
cAMP Assay. Increases in cAMP levels were determined using
HTRF technology (cAMP dynamic 2 bulk HTRF-Assay; Cisbio,
Codolet, France) in 384-well plate format according to the manufac-
turer’s protocol. Cells were stimulatedwith b2-agonists for 30minutes
in presence of 3-isobutyl-1-methylxanthine (Sigma-Aldrich) and then
lysed by using Cisbio reagents. The measurement was performed
with theMolecular Devices SpectraMax Paradigm (Molecular Devices
LLC, Sunnyvale, CA). Results were calculated from the 665/620 nm
ratio, and data were expressed in percentage of the DMSO-stimulated
control. The functional b3-AR assay was performed at Eurofins Panlabs
Taiwan Ltd.
Myotube Hypertrophy Assay. Human skMC were differenti-
ated tomyotubes in 12-well pates coatedwithMatrigel and stimulated
with compounds for 48 hours. Immunostaining with anti-myosin
heavy chain antibody (cat. no. 05-833; Upstate Biotechnology, Lake
Placid, NY) was performed and myotube diameters were determined
as described previously (Trendelenburg AU et al., 2009). Images
shown were taken with Cellomics CellInsight HCS Reader with
10 objective (ThermoFisher Scientific, Paisley, France).
Animals
Male Wistar Han or Sprague Dawley rats were purchased from
Charles River Laboratories (Sulzfeld, Germany or USA), acclimatized
to the facility for 7 days, housed in groups of two to three animals at
25°C with a 12:12-hour light-dark cycle, and fed a standard labora-
tory diet. Food and water were provided ad libitum. Female rhesus
monkeys were housed in a colony at Novartis Pharma AG. Besides
following the Guide for the Care and Use of Laboratory Animals, the
experiments described here were performed according to the regula-
tions effective in the Canton of Basel-City, Switzerland, as well as
East Hanover (NJ) and Cambridge (MA).
In Vitro Tissue Membrane Assays
Procedures for the preparation of cell membrane fragments
for assessment of b-AR activity have been described previously
(MacEwan et al., 1996; Beitzel et al., 2007). The gastrocnemius
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muscle and the heart were collected from 3- to 4-month-old male
Wistar rats. The frozen tissueswere pulverized in aCryopress (Microtec
Co., Ltd, Chiba, Japan) and homogenized in a buffer containing
20 mM HEPES, 0.25 M sucrose, 1 mM EGTA pH 7.0, and a protease
inhibitor cocktail (Roche Diagnostics, Rotkreuz, Switzerland). The homog-
enate was centrifuged at 1000g for 10 minutes, and the supernatants
were filtered through a polyamide mesh (pore size 250 mm) into an
ultracentrifuge tube. The filtered supernatants were further cleared
by centrifugation at 10,000g for 15 minutes, and the supernatant
containing cell membrane fragments was prepared by repeated
ultracentrifugation at 100,000g for 30 minutes to isolate the sarco-
lemma membrane. Enrichment in membrane fraction was validated
by WB (Supplemental Fig. 1). After this step, the cell membrane
pellets were resuspended in a buffer containing 10 mM HEPES,
0.1 mM EDTA pH 7.4, and a protease inhibitor cocktail. The cell
membrane suspensions and compounds (diluted in a buffer containing
30 mM HEPES pH 7.4, 20 mM phosphocreatine, 20 IU/ml creatine
phosphokinase, 20 mM GTP, 400 mM ATP, 10 mM MgCl2, 300 mM
IBMX, 200mMRolipram)weremixedwith a ratio of 1:1 and incubated
at room temperature for 30 minutes. Sequentially, HTRF cAMP
CisBio reagents were added, followed by measurement and analysis
(performed as described above).
In Vitro Isolated Organ Assays
Chronotropy in rabbit sinoatrial node: The right atrium was sepa-
rated from the rest of the heart (collected from New Zealand white
female rabbits from Charles River Laboratories). The preparations
were mounted in a tissue bath and kept at 37°C for at least 1 hour
of stabilization. The stabilization phase lasted at least 60 minutes
during the period that the sinoatrial (SA) pacemaker activity remained
stable for at least 20 minutes. Action potentials were intracellularly
recorded with a standard glass microelectrode filled with 3 M KCl,
connected to a high-input impedance-neutralizing microelectrode
amplifier VF-180 (Bio-Logic Science Instruments, Seyssinet-Pariset,
France). The action potentials were displayed on a digital oscilloscope
HM-407 [Rohde&Schwarz (HAMEG Instruments),Munich,Germany],
analyzed bymeans of high-resolution data acquisition systemNotocord-
hem software 4.2 (Notocord Systems, Le Pecq, France). Inotropy assay
in guinea pig left atria: The assay was conducted at Eurofins Panlabs
(Taipei, Taiwan). Left atria were isolated fromDunkinHartley–derived
male or female guinea pigs with body weights of 600 g, and the inotropy
response as measured by isometric changes in grams was evalu-
ated according to the method described elsewhere (Grodzinska and
Gryglewski, 1971). Vascular relaxation in rat aortic ring: The thoracic
aortas were isolated from Sprague Dawley rats, and cut into rings
2- to 3-mm long. The rings were mounted on stainless steel hooks
and suspended in organ glass chambers (Radnoti, Covina, CA).
Tension development was measured by isometric force transducers
159901A (Radnoti) connected to a data acquisition system, PowerLab
(ADInstruments, Oxford, UK). Cumulative dose-response curves to
formoterol and 5-HOB were obtained. Absolute tension of all points
was analyzed, and the relaxant response to each concentration of
compound was expressed as the percentage decrease from precon-
traction induced by 100 nM phenylephrine.
Effects on Hind Limb Muscle and Heart in Wistar Rats
Compound Administration. Formoterol and 5-HOB were sub-
cutaneously administered to rats using Alzet osmotic minipumps
(the model 2ML4 with pumping rate of 2.5 ml/h; Charles River
Laboratories) for 4 weeks. Formoterol was dissolved in 0.9% NaCl to
achieve doses at 0.003, 0.01, and 0.03 mg/kg per day, and 5-HOB was
dissolved in 20% Cremophor EL and ethanol mixed with a ratio of
1:2 in 0.9% NaCl to achieve doses at 0.01, 0.03, and 0.1 mg/kg per day
The dose range was selected to achieve a range of plasma compound
concentrations like that at steady state.
Evoked Force. After treatment with the compounds for 4 weeks,
the sciatic nerve was attached to a nerve-stimulating electrode
(Harvard Apparatus, Holliston, MA) and the Achilles tendon with
a piece of calcaneus was attached with a polyethylene thread
(Spiderwire 16/1135590; 0.30 mm/110 m; Pure Fishing, Hattersheim
Germany) to a force displacement transducer (Model FT10; Grass
Technologies, West Warwick, RI) under anesthesia. The knee and
ankle joints were immobilized with a clamp, and the stimulating
electrode was connected to an electrical stimulator (ADInstruments).
The force of contraction was acquired with PowerLab system and
analyzed using LabChartPro (ADInstruments).
Dissection and Data Analysis. The tibialis anterior, gastrocne-
mius, and soleus muscles were dissected and weighed. The brain
weight was also measured for normalization of heart weights (Sellers
et al., 2007). Body weight was expressed as percentage change from
day 0 as the start of treatment (initial body weight). Muscle weight
was normalized to initial body weight and then expressed as percent-
age change from the vehicle control group. The organ weight was
normalized to brain weight and then expressed as percentage change
from the control group.
Effects on Calf Muscle Mass and Ejection Fraction in
Wistar Rats
Compound Administration. Formoterol and 5-HOB were ad-
ministered subcutaneously to rats once daily for 4 weeks and then the
treatment was discontinued for 5 weeks. Formoterol was dissolved in
0.9% NaCl, and 5-HOB was dissolved in 50% PEG200 in distilled
water.
Magnetic Resonance Imaging Measurement and Data
Analysis. Magnetic resonance imaging (MRI) measurement was
performed in the rats under anesthesia with isoflurane at a concen-
tration of 1%–1.3%, using a Bruker Avance 7 T/30-cm wide-bore
instrument (Bruker BioSpin, Billerica, MA) equipped with a 12-cm
inner diameter (i.d.) actively shielded gradient insert. Two elec-
trocardiography (EKG) electrodes 3M Red Dots (3M; St. Paul, MN)
were attached. Respiration, body temperature, and EKG were mon-
itored throughout the experiment using the physiology monitoring
system by SA Instruments, Inc. Cardiac images were acquired in the
standard cardiac views which are aligned along the principle axes of
the organ. The segmentation and length measurements were per-
formed for both diastole and systole. Left-ventricular volume was
calculated by integrating the blood pool volume using a truncated cone
model, and ejection fraction was also calculated. Muscle volume was
measured using an imaging method that separated water and fat
signals (Tsao and Jiang, 2013). The three-dimensional water-only
image was reconstructed in Matlab (Mathworks). Lower leg muscle
volume was calculated using in-house generated software.
Effects on Heart Rate and Mean Arterial Pressure in
Wistar Rats
Surgical Procedure. Rats were surgically instrumented with a
chronically indwelling femoral arterial catheter to allow direct mea-
surement of arterial blood pressure and repeated blood sampling, and
with a catheter terminating subcutaneously to allow subcutaneous
administration of vehicle or compounds.
A femoral artery was isolated and a catheter inserted. The
catheter was tunneled subcutaneously and exteriorized in the mid-
dorsal abdominal region. The catheter exited through a subcuta-
neously anchored skin button/tether/swivel system that allowed
the animal to move unrestrained in a specialized Plexiglas wire-
bottom cage.
For implanting the subcutaneous catheter, a narrow tunnel was
created by inserting a Teflon catheter/needle subcutaneously from
the skin button incision site to the midscapular region. The tip of the
catheter/needle was pushed through the midscapular skin and the
needle removed, leaving the Teflon catheter intact and still protruding
through the skin. The hub of the Teflon catheterwas cut off. The Tygon
subcutaneous catheter was inserted into the Teflon catheter so that
the tip of the s.c. catheter extended slightly beyond the tip of the Teflon
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catheter. The Tygon catheter and tubing were clamped at the exit site
from the skin. The Tygon catheter was anchored at the skin button
incision site. The Tygon and Teflon tubings were unclamped and
the Teflon catheter was removed through the skin puncture wound.
The midscapular skin was then lifted to retract the tip of the Tygon
catheter subcutaneously. The Tygon catheter was exteriorized through
the spring tether along with the arterial catheter.
Compound Administration and Data Acquisition. Formo-
terol was dissolved in 0.9% NaCl, and 5-HOB was dissolved in 0.27%
2-hydroxypropyl b-cyclodextrin in saline. The compound or vehicle
was administered subcutaneously via the implanted catheter over
40–45 seconds followed by an air flush over 10–15 seconds. The
arterial catheter was attached to a precalibrated blood pressure
transducer, Statham P23 (AMETEK Power Instruments, Rochester,
NY) for continuousmonitoring of arterial pressure. The pulsatile blood
pressure signals were conditioned and amplified with Gould pream-
plifiers and further processedwith aModular Instruments, Inc. digital
data acquisition system. For an individual rat, mean arterial pressure
and heart rate were continuously derived from all beats over consecu-
tive 15-second intervals.
Effects on Heart Rate in Rhesus Monkeys
Formoterol and 5-HOB were administered subcutaneously to rhesus
monkeys at the age of 6–8 years old with a body weight around 5–7 kg.
Formoterol was dissolved in 0.9% NaCl, and 5-HOB was dissolved
in 2.5% Pluronic F-127 in 0.9% NaCl. The monkeys were restrained
on a chair up to 4 hours after subcutaneous administration and
then returned to their pens. Heart rate, potassium, and glucose were
measured. Heart rate was measured by a Surgivet V3304 device
(Smiths Medical, Adliswil, Switzerland). Blood samples were col-
lected at 0, 0.08, 0.25, 0.5, 1, 2, and 4 hours on the chair, and blood
glucose was measured with a glucometer (Accu-Check Aviva Nano;
Roche Diagnostics). Potassium concentration was measured by an
automated blood biochemistry analyzer (NOVA CRT8A; Laboratory
Systeme Flükiger, Menziken, Switzerland).
Compound Concentration Monitoring
In some experiments, compound concentrations in plasma were
measured to assess the relationship between concentration and
response. Plasma protein was precipitated by mixing with acetoni-
trile and removed by centrifugation. The remaining solvent in the
supernatant was evaporated, dissolved, and injected into a liquid
chromatography–tandemmass spectrometry system, AB SCIEXQTRAP
5500 (AB Sciex, Baden, Switzerland), for analysis.
Statistical Analysis
Statistical analysis was carried out using GraphPad Prism; com-
parison of two groups with unpaired t test, multiple comparisons
with Bonferroni’s test or Dunnett’s test following one-way analysis of
variance (ANOVA), or Holm-Sidak test or Sidak test following two-
way ANOVA as indicated in each figure or table legend. Differences
were considered to be significant when the probability value was,0.05.
Concentration-response data were evaluated by sigmoid curve fit-
ting using XLfit (IDBS) yielding EC50 values (concentrations causing
half-maximal effects) and Emax (maximal effects).
Results
Binding Affinity and Kinetic Characteristics. The
affinity of 5-HOB and formoterol for the b2-AR was assessed
in a [3H]-DHA radioligand competition binding assay using
membranes derived from CHO cells expressing the human
b2-AR (Table 1). Both agonists showed high binding affinity
for the b2-AR in the nanomolar range, with 5-HOB exhibit-
ing an approximately 10-fold higher binding affinity than
formoterol (Table 1). We also measured binding kinetic param-
eters of both agonists using the competition-association binding
method first described by Motulsky and Mahan (1984). 5-HOB
showed a longer residence time at the human b2-AR, with
a slower dissociation half-life compared with formoterol.
The mean kinetic kon and koff values determined for 5-HOB
were 7.43  108 M21 min21 and 0.733 minutes21, respec-
tively, producing a kinetically derived dissociation constant
Kd (koff/kon) value of 1.08 6 0.14 nM, which is in excellent
agreement with the equilibrium Ki value obtained from
competition binding experiments. Displacement of [3H]-DHA
from the b2-AR by b2 agonists was determined in the presence
of 1 mM GTP to uncouple the receptor from downstream G
proteins; therefore, these affinity measurements are reflective
of a low-affinity form of the receptor (Kent et al., 1980). 5-HOB
had higher binding affinity to the low-affinity form of the
receptor compared with formoterol.
In Vitro Functional Activity of 5-HOB in Cellular
Systems and Membrane Extracts. The functional activ-
ity and receptor selectivity of 5-HOB were evaluated by the
measurement of cAMP production in CHO or HEK293 cells
stably expressing a comparable level of each of the three human
b-AR subtypes: b1, b2, and b3 (Table 2). 5-HOB showed a potent
agonistic response at the human b2-AR (EC50 5 3.5 nM) and
high selectivity over the other subtypes, b1-AR and b3-AR
(EC50 5 793 and 925 nM, respectively). In comparison with
formoterol, 5-HOB showed a similar selectivity profile on all
three human b-AR subtypes but with an overall 10-fold lower
potency. Importantly, a clear difference in themaximum effect
(Emax) was observed between the two agonists on the human
b1-AR, 40% 6 6.8% for 5-HOB compared with 84% 6 6.5%
for formoterol (P , 0.0001 by t test), which is considered to
be advantageous for 5-HOB in terms of cardiac safety, as the
b1-AR is the main subtype expressed in the heart.
On the basis of the above b2-AR functional activity and
binding data we performed a modeling simulation of recep-
tor occupancy at the EC40 of cAMP response. The simulation
revealed that 5-HOB requires a much higher degree of b2-AR
receptor occupancy (70.4%), relative to formoterol (1.8%), to
produce an equivalent effect (Table 2), indicating a lower
intrinsic efficacy of 5-HOB.
In addition, functional cAMP assays were conducted using
the relevant primary human, rat, dog, and monkey cells with
endogenous expression of b1- and b2-ARs. 5-HOB was shown
to be highly potent and efficacious at inducing cAMP pro-
duction in skeletal muscle myotubes, in a manner similar to
formoterol (Table 3). However, 5-HOB was less efficacious
(appearing as a partial agonist) than formoterol at induc-
ing cAMP production in iPS-derived human cardiomyocytes
and rat cardiomyocytes compared with the effect on skeletal
TABLE 1
Binding and kinetic parameters of 5-HOB and formoterol for the human
b2-AR
The values are expressed as mean 6 S.E.M. of at least three independent
experiments.
5-HOB Formoterol
Equilibrium Ki (nM) 1.62 6 0.55 12.9 6 4.3
kon (M
21min21) 7.43 6 2.42  108 1.78 6 0.21  108
koff (min
21) 0.73 6 0.13 3.0 6 0.4
Kinetic Kd (nM) 1.08 6 0.14 16.80 6 0.04
t1/2 of dissociation (s) 57 14
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muscle myotubes. The EC50 values were comparable among
species, indicating that cross-species differences seem to be
minimal in terms of cAMP responses in these cell types.
The induction of cAMP was also evaluated in cell mem-
branes isolated from rat skeletal muscle and heart tissue
(Fig. 1B; Table 4). The effect of 5-HOB on cAMP induction
was quite prominent in rat skeletal muscle membranes
but much weaker in rat heart membranes. Compared with
formoterol, 5-HOB demonstrated comparable maximal efficacy
on skeletal muscle membranes and a significantly reduced
efficacy on heart membranes (P 5 0.005 by t test), clearly
demonstrating the tissue selective characteristics of 5-HOB.
In conclusion, all in vitro functional studies point to a potent
effect of 5-HOB on skeletal muscle comparable to that of
formoterol, and an intrinsically weaker effect of 5-HOB on the
cardiac tissue (membranes or cells) including in comparison
with formoterol.
In Vitro Effect on Skeletal Muscle Hypertrophy. The
functional activity of 5-HOB was additionally tested in an
in vitro human primary skeletal muscle hypertrophy assay
(Fig. 2). 5-HOB induced a significant increase in skeletal
myotube diameter, an effect that was blocked by the b2-AR
antagonist ICI-118,551 but not by the selective b1-AR antag-
onist CGP20712. These data indicate that skeletal muscle
hypertrophy is specifically induced by agonistic activity of
5-HOB on the b2-AR.
In Vitro Functional Activity of 5-HOB in Isolated
Organs. To assess tissue selectivity, the effects of 5-HOB on
the cardiovascular system have been evaluated in in vitro
isolated-organ assays: rabbit sinoatrial node for measuring
chronotropic effects (Fig. 3), guinea pig left atria formeasuring
inotropic effects (Table 5), and rat aortic ring for measur-
ing vascular relaxation effects (Table 5). Formoterol was shown
to be a potent inducer of sinoatrial node pacemaker activity
(Fig. 3B;111% at 5 nM and145% at 150 nM), whereas 5-HOB
showed a weak effect on chronotropy up to a concentration
of 150 nM (Fig. 3C; 16.5% from baseline). No direct effects
of 5-HOB were noted on inotropy at concentrations of up to
10 mM, while formoterol induced atrial contractility with an
EC50 of 17 nM. In an aortic ring relaxation assay, formoterol
showed a potent effect with an EC50 of 0.8 nM, but 5-HOB
showed a weaker effect with an EC50 of 31 nM. Overall, the
effect of 5-HOB on chronotropy, inotropy, and vascular re-
laxation were observed only at the highest concentrations and
were negligible in the concentration range producing skeletal
muscle changes described below.
In Vivo 5-HOB Effects on Skeletal Muscle and on
Heart in Wistar Rats. The effect of 5-HOB on skeletal
muscle and heart weight was evaluated in Wistar rats with
subcutaneously implanted osmotic minipumps, in compar-
ison with the effect of formoterol. Formoterol significantly
increased both skeletal muscle and heart weight to a similar
extent: 13% and 15% at 0.003 mg/kg (both P , 0.05), 20% and
17% at 0.01 mg/kg (both P , 0.05), and 27% and 21% at
0.03 mg/kg (both P , 0.05), for the weight of pooled hind
limb skeletal muscle and heart in comparison with the vehicle
control, respectively (Fig. 4A; Supplemental Table 1). The
delta in weight changes between skeletal muscle and heart
were not statistically significant at all doses for formoterol
(P. 0.05, Supplemental Table 1). In contrast, 5-HOB showed
an increase selective for skeletal muscle weight over heart
weight: 11% and 6.9% at 0.01 mg/kg (P , 0.05, P 5 0.2324),
17% and 9.3% at 0.03 mg/kg (P , 0.05, P 5 0.0939), and 26%
and 12% at 0.1 mg/kg (both P , 0.05), for the weight of pooled
hind limb skeletal muscle and heart in comparison with the
vehicle control, respectively (Fig. 4B; Supplemental Table 1).
It should be noted that the weight changes in the heart at the
two lower doses were not statistically significant from the
vehicle control (Fig. 4B). The delta in weight changes between
skeletal muscle and heart were not statistically different at
lower doses and became statistically significant at 0.1 mg/kg
(Supplemental Table 1). A significant increase in evoked force
was also observed in parallel to skeletal muscle hypertrophy
for each formoterol and 5-HOB (tested at 0.01 mg/kg, Fig. 4C),
and the increase in evoked force between formoterol and 5-HOB
was not statistically significant (P5 0.8086 by t test). The doses
of b2-AR agonists showed comparable increase in plasma expo-
sure across the three doses (Supplemental Table 1). Therefore,
TABLE 3
Functional activity of 5-HOB and formoterol in primary cells with endogenous expression of b-ARs
Emax values were determined relative to formoterol, where formoterol was defined as 100%. The values are expressed as




EC50 Emax EC50 Emax
nM % nM %
Skeletal muscle myotubes Rat 1.9 6 0.4 104 6 0.8 0.1 6 0.02 100 6 0.0
Dog 2.1 6 0.2 89 6 0.8 0.6 6 0.03 100 6 0.0
Monkey 5.1 6 0.8 90 6 3.7 1.5 6 0.37 100 6 0.0
Human 1.7 6 0.1 96 6 0.3 0.3 6 0.01 100 6 0.0
Cardiomyocytes Rat 4.4 6 0.5 72 6 0.3 1.6 6 0.13 100 6 0.0
Human iPS-derived 3.4 6 0.2 84 6 2.5 0.5 6 0.03 100 6 0.0
TABLE 2
Functional activity and selectivity of 5-HOB and formoterol against the
different human b-AR subtypes
b1-AR and b2-AR were expressed in CHO cells; b3-AR was expressed in HEK293
cells. Emax values were determined relative to isoprenaline, a reference nonselective




EC50 Emax EC50 Emax
nM % nM %
b1-AR 793 6 92 40 6 1.7 67 6 3.8 84 6 1.6
b2-AR 3.5 6 0.3 93 6 0.7 0.3 6 0.03 97 6 1.0
b3-AR 925 6 11 97 6 0.7 97 6 1.4 113 6 7
b2-AR occupancy at %
control [EC40]
70.4 1.8
5-HOB, Skeletal Muscle Selective b2-Agonist 193
 at A








the relationship between plasma concentration and skeletal
muscle effects were similar for both formoterol and 5-HOB.
To gain further insights into the effect of formoterol and
5-HOB on skeletal muscle mass and ejection fraction as a
measure of cardiac function, longitudinal monitoring with
MRI was conducted. Once daily subcutaneous treatment of
4 weeks followed by washout for 5 weeks allowed an assess-
ment of duration of action and reversibility. The effect of
5-HOB on skeletal muscle mass was equivalent to the effect
with formoterol at the same dose level (0.03 mg/kg QD), and
this hypertrophy effect was maintained for 5 weeks after
cessation of treatment, compared with the vehicle-treated
groups (Fig. 5A). In the formoterol- and 5-HOB-treated groups,
the increases in skeletal muscle mass compared with the
vehicle control were statistically significant at 2, 4, 6, and
9 weeks (P , 0.05; Supplemental Table 2). There was no
statistical difference on the increases in skeletal muscle
mass between formoterol and 5-HOB (P. 0.05; Supplemental
Table 2). In contrast to the effect on muscle volume, there was
a clear difference in ejection fraction between formoterol and
5-HOB. During the 4-week treatment period, formoterol
significantly reduced ejection fraction compared with the
vehicle control (P , 0.05 at 2 and 4 weeks), whereas 5-HOB
did not (P . 0.05 at all time points) (Fig. 5B; Supplemental
Table 2). The change in ejection fraction between formoterol
and 5-HOBwas statistically significant at 2 weeks (P, 0.0001)
and became not significantly different after 4 weeks (P . 0.05
at 4, 6 and 9 weeks) (Supplemental Table 2). During the
washout period, the effect of formoterol on ejection fraction
was found to be reversible, and returned close to baseline.
Cardiovascular Effects in Wistar Rats and Rhesus
Monkeys. To evaluate if 5-HOB would show attenuated
acute cardiovascular effects in vivo after a single subcuta-
neous treatment, as indicated by the cellular and isolated
organ assays, we monitored heart rate in Wistar rats and
rhesus monkeys. In the rat, formoterol induced a maximum
heart rate increase of approximately 150 bpm at the three
highest doses tested (0.01–0.1 mg/kg), and a nearly maxi-
mal effect at the lowest dose (0.003 mg/kg, Cmax 5 2.2 nM)
within 5 minutes of dosing, as shown in Fig. 6A. In contrast,
compared with the vehicle control, the effect of 5-HOB on
heart rate was apparent only at the highest tested dose
(0.3 mg/kg, Cmax 5 18 nM) with an increased heart rate of
158 bpm (a 14% increase from the baseline) and showed
almost no effect at the lower doses (Fig. 6B). Thus, formoterol
is more potent than 5-HOB in inducing a positive chronotropic
effect, as reflected by the relative shift in the dose-response
relationships (Fig. 6C). The effect of formoterol was statisti-
cally significant at all doses, and the effect of 5-HOB was
statistically significant only at 0.3 mg/kg (Supplemental
Table 3). Unlike the changes in heart rate, formoterol dose
dependently decreased mean arterial pressure by a maximum
of approximately 30 mm Hg, whereas the effect of 5-HOB on
mean arterial pressure was again apparent only at 0.3 mg/kg
(Fig. 6D). The effect of formoterol was statistically signifi-
cant above 0.01 mg/kg and the effect of 5-HOB was statis-
tically significant only at 0.3 mg/kg (Supplemental Table 3).
Nevertheless, formoterol was still 1.5–2 orders of magni-
tude more potent than 5-HOB in eliciting a vasodepressor
response.
In rhesus monkeys, a single subcutaneous dose of formo-
terol increased heart rate by 160 bpm at 5 minutes postdos-
ing (132% from predose baseline) at 0.01 mg/kg with plasma
concentration of 7.7 nM (Fig. 7A). In contrast, a single subcu-
taneous dose of 5-HOB showed a heart rate change of 117 bpm
at 30minutes postdosing (19.2% from predose baseline), which
is in the range of the variability observed in the control groups
Fig. 2. Hypertrophy in human primary skeletal muscle
myotubes. (A) Differentiated myotubes treated with DMSO
control, formoterol (1 mM), or 5-HOB (1 mM) for 48 hours
were stained with anti–myosin heavy chain (MyHC). Shown
are representative pictures. (B) In vitro differentiated human
skeletal muscle myotubes were treated with 5-HOB (1 mM)
in the absence or presence of a b1-antagonist (CGP20712A,
1 mM) or a b2-antagonist (ICI-118’551, 1 mM) for 48 hours,
and changes in myotube diameters were measured. Data are
expressed as percentage increase compared with the DMSO
control treatment (as 100%). The values are expressed as
mean 6 S.E.M. of three independent experiments. **P ,
0.01; ***P , 0.001 increase vs. DMSO control (one-way
ANOVA, followed by Bonferroni’s test).
TABLE 4
Functional activity of 5-HOB and formoterol in cell membranes isolated
from rat tissues
% cAMP responses was determined relative to the Emax of formoterol in skeletal
muscle membranes. The EC50 and Emax values 6 S.E.M. of experiments from three
independent membrane preparations, each performed with seven concentrations of
compounds (10-fold dilutions) in triplicates.
cAMP Response
5-HOB Formoterol
EC50 Emax EC50 Emax
nM % nM %
Skeletal muscle 80 6 17 92 6 1 6 6 0.3 100 6 0
Heart 361 6 179 14 6 2 62 6 8 53 6 4
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after being returned to their pens, at 0.03 mg/kg with
plasma concentration of 4.4 nM (Fig. 7A). There was no
obvious heart rate change observed with 5-HOB dosed
at 0.01 mg/kg. The effect on heart rate with 5-HOB was
clearly lower than that of formoterol when plasma concen-
trations to heart rate response relationships are compared,
as illustrated in Fig. 7B. Blood glucose and serum potas-
sium levels were also evaluated as well-described b2-AR-
mediated pharmacodynamic markers (Supplemental Fig. 3):
Formoterol dosed at 0.01 mg/kg induced hyperglycemia
between140% and143% compared with predose baseline,
whereas 5-HOB dosed at 0.03 mg/kg increased blood glucose
by around 13%, which is in the range of variation observed
in the control groups after they were returned to their pens,
compared with the predose baseline levels. There was no
obvious change in blood glucose levels observed with 5-HOB
dosed at 0.01 mg/kg. The hyperglycemic effect of 5-HOB
was clearly lower than that of formoterol. Moreover, the
degree of hypokalemic effects showed a similar trend as
observed with the blood glucose changes, and 5-HOB clearly
showed a lesser effect on serum potassium levels (Supple-
mental Fig. 3). Overall, 5-HOB has a favorable profile in
terms of cardiac and metabolic effects compared with formo-
terol, i.e., on heart rate, blood glucose, and serum potassium
changes.
Discussion
In the present study, we have investigated the preclinical
pharmacological profile of 5-HOB, a novel b2-AR agonist with
a potent anabolic effect on skeletal muscle but with mark-
edly attenuated cardiovascular effects, which was investi-
gated for the treatment of skeletal muscle wasting conditions
in which cardiovascular effects associated with this class of
drugs would be undesirable. To benchmark the profile, 5-HOB
was compared with formoterol as a class representative
and well characterized b2-AR agonist. Before this study
was performed, it had not been previously demonstrated
that one could achieve relative tissue selectivity with a
b2-AR agonist.
In a radioligand binding assay, 5-HOB demonstrated
high affinity for the human b2-AR. The b2-AR binding
affinity translated into observed in vitro efficacy, exempli-
fied by the rise in intracellular cAMP in which 5-HOB had
high potency in the nanomolar range on the b2-AR and
displayed selectivity over b1-AR and b3-AR. The receptor
selectivity profile of 5-HOB against the b-AR subtypes is
comparable to that of formoterol but with lower intrinsic
efficacy on the b1-AR, which is advantageous for 5-HOB in
terms of cardiac safety as the b1-AR is the main subtype
expressed in the heart (Zheng et al., 2005) and implicated in
pathologic remodeling effects (Engelhardt et al., 1999;Morisco
et al., 2001). While the b2-AR also contributes to cardiovascu-
lar effects (Molenaar et al 2000), studies in b-AR-subtype
knockout mice imply that the b1-AR plays a predominant role
in catecholamine-mediated regulation of heart rate and myo-
cardial contractility (Chruscinski et al., 1999; Rohrer et al.,
1999). This suggests that b2-AR-selective agonists could offer
an advantage for a reduced cardiovascular side-effect profile.
Therefore, lower efficacy of 5-HOB on the b1-AR compared
with formoterol might contribute to the compound’s favorable
cardiac profile. The relevance of b3/b2 selectivity is currently
less clear, although it has been shown that activation of
b3-AR in the ventricle may cause negative inotropic effects in
the heart (Gauthier et al., 2000; Angelone et al., 2008). The
main roles described for the b3-AR are in lipolysis and bladder
relaxation, i.e., tissues in which this receptor subtype is
predominant (Philipson, 2002; Yamaguchi, 2002). Our studies
have also investigated b2-AR agonist–mediated stimulation
in systems with an endogenous distribution of receptors: in
primary cells and in cell membranes prepared from rat
tissues. In a functional cAMP assay using primary skeletal
muscle cells, 5-HOB was shown to be a highly efficacious
agonist, but in cardiomyocytes 5-HOB behaved as a partial
agonist with a reduced intrinsic efficacy versus formoterol.
Consistent with the result obtained in skeletal muscle myotubes
and cardiomyocytes, both 5-HOB and formoterol appeared
TABLE 5
Effects of 5-HOB and formoterol on inotropy and vascular relaxation
Left atrium was isolated from Dunkin Hartley guinea pigs and aortic ring was
isolated from Sprague Dawley rats. The values are expressed as means of n = 2 for




Vascular relaxation 0.8 31
Fig. 3. Effects of formoterol and 5-HOB on the beating rate of rabbit
sinoatrial node. (A) values are means 6 S.E.M. (n = 5 to 6) and % changes
from baseline values. (B) Superimposed SA action potentials exposed to
formoterol (mean of n = 5). (C) Superimposed SA action potential exposed
to 5-HOB (mean of n = 6).
5-HOB, Skeletal Muscle Selective b2-Agonist 195
 at A








to be equally efficacious agonists in skeletal muscles mem-
branes, whereas 5-HOB was a less efficacious in heart
membranes compared with formoterol. Like differences
between the two agonists were also observed in the assays
using isolated organs for evaluating the effect on the cardio-
vascular system. Thus, 5-HOB showed only a weak effect on
pacemaker activity and on aortic ring relaxation, and no effect
on atrial contractility. In contrast, formoterol exerted potent
effects on chronotropy, inotropy, and vascular relaxation, as
would be expected from a conventional b2-AR agonist.
In our studies both b2-AR agonists, 5-HOB and formoterol,
displayed comparable anabolic action on skeletal muscle
in vitro and in vivo. In addition, we demonstrated that
the 5-HOB-induced skeletal muscle hypertrophy is b2-AR
mediated. In vitro, 5-HOB promoted significant hypertro-
phy in human skeletal muscle myotubes and this effect was
blocked by the b2-AR antagonist ICI-118,551, but not by the
b1-AR selective antagonist CGP20712. This is in line with
what has previously been shown in vivo by others: the b2-AR
agonist (clenbuterol) mediated skeletal muscle hypertrophy
can be blocked by selective b2-AR antagonists, or by genetic
deletion of the b2-AR (Choo et al., 1992; Hinkle et al., 2002).
Also in our in vitro assay formoterol- and clenbuterol-induced
hypertrophy were blocked by ICI-118,551 (Supplemental
Fig. 2). In line with our in vitro hypertrophy data, in rat
studies both 5-HOB and formoterol were capable of induc-
ing comparable strong skeletal muscle hypertrophy as well
as increasing muscle function measured by evoked force
Fig. 5. Time-course changes of hind limb muscle mass (A)
and ejection fraction (B) in Wistar rats. Changes in hind
limb muscle and ejection fraction were evaluated by MRI
during treatment with formoterol and 5-HOB once daily
subcutaneously at 0.03 mg/kg for 4 weeks and during
washout for 5 weeks. Values are means 6 S.E.M. (n =
6–8). **P , 0.01 vs. vehicle control (Holm-Sidak test follow-
ing two-way repeated measurement ANOVA).
Fig. 4. Dose-response effects of formoterol (A) and 5-HOB
(B) on the weight of hind limb muscle and heart in Wistar
rats. Effects of formoterol and 5-HOB on evoked force of
hind limb muscle (C). Compounds were administered with
subcutaneously implanted Alzet minipump for 4 weeks.
Values are means 6 S.E.M. or mean (n = 5 to 6), *P , 0.05;
**P , 0.01 vs. vehicle control (Dunnett’s test following one-
way ANOVA).
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at an equivalent plasma concentration. However, 5-HOB
caused lower increase in heart weight compared with skeletal
muscle weight while formoterol produced nearly equiva-
lent increases in both heart and skeletal muscle weight. This
selective action of 5-HOB on skeletal muscle could be further
demonstrated by the lack of an effect on cardiac function, as
measured by ejection fraction, in comparison with formoterol
which significantly decreased ejection fraction during the treat-
ment period. It seems clear that the increased heart rate
was associated with the decreased cardiac function in the
formoterol treatment group.
When acute cardiovascular effects were evaluated, formo-
terol at a dose of 0.003 mg/kg, with a Cmax of 2.2 nM, was
sufficient to elicit almost the maximum heart rate increase
of approximately 150 bpm (approx. 35%–40% increase) in the
rat. In contrast, although the highest doses of 5-HOB achieved
approximately 10-fold higher Cmax value (18 nM at 0.3 mg/kg),
heart rate was increased by only 58 bpm. The effect of 5-HOB
on mean arterial pressure was also less compared with
formoterol. Overall, 5-HOB was about 1.5–2 orders of magni-
tude less potent than formoterol in eliciting cardiovascular
responses. These differences in heart rate responses between
formoterol and 5-HOB were also well reproduced in a similar
plasma concentration range in the rhesus monkey. These
in vivo findings clearly reflect the results obtained with
isolated organs for inducing cardiovascular effects, imply-
ing that 5-HOB is indeed a partial agonist, not only in the
cardiovascular system, but also in other organs such as the
liver based upon the effect on glucose levels (Supplemental
Fig. 3). The lack of effect on cardiac function as well as the
Fig. 7. Heart rate changes in rhesus monkeys after single
subcutaneous treatment with formoterol or 5-HOB (A).
Heart rate was measured with a Surgivet V3304 device
under restrained condition. Relationships of plasma concen-
tration (nanomolar) to heart rate response (bpm) (B). Values
are expressed as means 6 S.E.M. (n = 6) of absolute values.
Fig. 6. Heart rate changes in Wistar rats after single
subcutaneous treatment with formoterol (A) or 5-HOB
(B). Dose response (0–10 minute average) plots of formoterol
and 5-HOB for heart rate (C) and mean arterial pressure (D).
Values are expressed as means (A and B) or means6 S.E.M.
(C and D) (n = 3 to 4) of changes from predose baseline values.
*P , 0.05; **P , 0.01 vs. vehicle control (Dunnett’s test
following one-way ANOVA).
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attenuated acute cardiovascular responses with 5-HOB pro-
vide a clear advantage over conventional b2-AR agonists, such
as formoterol, which apparently do not exhibit such tissue
selectivity. What is particularly encouraging were the effects
of 5-HOB on rhesus monkeys. In these animals, formoterol
had a significant effect on heart rate even at the lowest dose,
inducing a 60 bpm increase; in contrast, 5-HOB did not cause a
statistically significant effect, even at therapeutic levels.
As discussed above, the attenuated effect of 5-HOB on
heart rate could be partially explained by its receptor selectiv-
ity for the b2-over the b1-AR, detected in in vitro functional
studies. However, other factors may contribute to the greater
effect of 5-HOB on skeletal muscles compared with effects on
the heart. The differential responses between tissues may also
be related to differences in absolute b2-AR numbers, as well as
differences in b2-AR/G protein/AC ratios between the different
tissue types. A drug that is a partial agonist in one tissue could
also be a full agonist in a different tissue wherein either
receptor density or receptor-to-response coupling efficiency
is relatively high. Supporting this notion, it has been shown
for the partial agonist salmeterol that the maximal agonist-
mediated stimulation of cAMP production can be increased
through the elevation of total levels of b2-AR (McDonnell
et al., 1998). Additionally, other studies have demonstrated
that enhanced expression of AC enables greater maximal
cAMP generation following receptor activation (MacEwan
et al., 1996). Our data clearly demonstrate that 5-HOB shows
the characteristics of a partial agonist: in cAMP functional
assays, it displayed partial efficacy in both cardiomyocytes
and membranes isolated from the heart. On the other hand,
we detected higher b2-AR expression at the mRNA level in
skeletal muscle compared with heart tissue in the rat, and in
cells isolated from these organs (Supplemental Fig. 4). Thus,
in skeletal muscle tissue, a lower intrinsic efficacy agonist
such as 5-HOB may be able to provoke a maximal functional
response because the receptor density is relatively high and,
or, the receptor reserve is relatively large. In contrast, in the
heart with a lower level of receptor expression a lower intrin-
sic activity compound, such as 5-HOB, would have minimal
efficacy. Interestingly, such tissue selectivity has been described
previously for adenosine A1 receptor agonists. Low intrinsic
efficacy adenosine A1 receptor agonists can reduce lipolysis
at concentrations that do not cause effects on heart rate due to
a greater receptor reserve in adipose tissue compared with
cardiac tissue (Wu et al., 2001; Fatholahi et al., 2006).
In summary, the preclinical data reported in this study
show that 5-HOB is a potent, selective b2-AR agonist that is
effective in promoting skeletal muscle growth. Furthermore,
5-HOB displays tissue selectivity and reduced cardiovascu-
lar effects, compared with the well-described representa-
tive b2-AR agonist formoterol in preclinical studies. Hence,
these data suggest that 5-HOB may provide a new valuable
treatment option for muscle atrophy conditions. Clinical studies
will determine whether 5-HOB has the potential for re-
duced cardiac side effects at therapeutic doses in humans
compared with other conventional b2-AR agonists, such as
formoterol.
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